Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 67017-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- LGMN antibody
- Antibody type
- Monoclonal
- Description
- LGMN antibody (Cat. #67017-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1F2B12
- Vial size
- 20ul, 150ul
Submitted references Legumain-Triggered Macrocyclization of Radiofluorinated Tracer for Enhanced PET Imaging.
Cathepsin L prevents the accumulation of alpha-synuclein fibrils in the cell.
The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Legumain affects the PI3K/AKT tumor progression pathway in retinoblastoma.
Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer.
A "dual-guide" bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence.
Legumain Promotes Gastric Cancer Progression Through Tumor-associated Macrophages In vitro and In vivo.
Gao X, Wang Q, Yang X, Fang J, Li H, Xi H, Lin J, Qiu L
Bioconjugate chemistry 2024 May 15;35(5):665-673
Bioconjugate chemistry 2024 May 15;35(5):665-673
Cathepsin L prevents the accumulation of alpha-synuclein fibrils in the cell.
Matsuki A, Watanabe Y, Hashimoto S, Hoshino A, Matoba S
Genes to cells : devoted to molecular & cellular mechanisms 2024 Apr;29(4):328-336
Genes to cells : devoted to molecular & cellular mechanisms 2024 Apr;29(4):328-336
The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Xuan Z, Fang L, Zhang G, Zhang X, Jiang J, Wang K, Huang P
Journal of molecular neuroscience : MN 2023 Jan;73(1):1-14
Journal of molecular neuroscience : MN 2023 Jan;73(1):1-14
Legumain affects the PI3K/AKT tumor progression pathway in retinoblastoma.
Tang Q, Xu F, Lin J, Zhang C, Liu X, Dong L, Zhao J, Zhu L, Lin T
Experimental eye research 2022 Nov;224:109221
Experimental eye research 2022 Nov;224:109221
Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer.
Ren K, Qiu Y, Yu Q, He J, Mei L, Liu Y, Li J, Wang X, Li M, Zhang Z, He Q
International journal of pharmaceutics 2021 Sep 25;607:120975
International journal of pharmaceutics 2021 Sep 25;607:120975
A "dual-guide" bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence.
Qiu Y, Ren K, Zhao W, Yu Q, Guo R, He J, Mei L, Liu Y, Tang J, Xu S, Li J, Wei J, Li M, Zhang Z, He Q
Journal of controlled release : official journal of the Controlled Release Society 2021 Jan 10;329:191-204
Journal of controlled release : official journal of the Controlled Release Society 2021 Jan 10;329:191-204
Legumain Promotes Gastric Cancer Progression Through Tumor-associated Macrophages In vitro and In vivo.
Wang H, Chen B, Lin Y, Zhou Y, Li X
International journal of biological sciences 2020;16(1):172-180
International journal of biological sciences 2020;16(1):172-180
No comments: Submit comment
No validations: Submit validation data